Stockreport

Intersect ENT Announces FDA Approval of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps

Intersect ENT, Inc.  (XENT) 
Last intersect ent, inc. earnings: 2/24 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intersectent.com/investor-relations
PDF Product Offers Targeted Relief for Managing Chronic Condition MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company d [Read more]